Athira Pharma, Inc. (ATHA)
Largest Insider Buys in Sector
ATHA Stock Price History Chart
ATHA Stock Performance
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including …
Insider Activity of Athira Pharma, Inc.
Over the last 12 months, insiders at Athira Pharma, Inc. have bought $1.56M and sold $46,454 worth of Athira Pharma, Inc. stock.
On average, over the past 5 years, insiders at Athira Pharma, Inc. have bought $22.92M and sold $36,925 worth of stock each year.
Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC () — $26.33M. Romano Kelly A (director) — $100,051.
The last purchase of 27,400 shares for transaction amount of $66,179 was made by Romano Kelly A (director) on 2024‑06‑24.
List of Insider Buy and Sell Transactions, Athira Pharma, Inc.
| 2024-09-05 | Sale | President and CEO | 5,032 0.0132% | $0.57 | $2,848 | -4.83% | ||
| 2024-09-05 | Sale | CFO and Chief Business Officer | 1,272 0.0033% | $0.57 | $720 | -4.83% | ||
| 2024-09-05 | Sale | CHIEF SCIENTIFIC OFFICER | 2,525 0.0066% | $0.57 | $1,429 | -4.83% | ||
| 2024-09-05 | Sale | GENERAL COUNSEL | 2,525 0.0066% | $0.57 | $1,429 | -4.83% | ||
| 2024-09-05 | Sale | COO and CDO | 2,525 0.0066% | $0.57 | $1,429 | -4.83% | ||
| 2024-06-24 | director | 27,400 0.0729% | $2.42 | $66,179 | -73.52% | |||
| 2024-06-21 | director | 15,000 0.0347% | $2.26 | $33,872 | -73.13% | |||
| 2024-01-05 | Sale | Chief Executive Officer | 4,820 0.0129% | $2.91 | $14,026 | -12.20% | ||
| 2024-01-05 | Sale | CFO AND CHIEF BUSINESS OFFICER | 1,208 0.0032% | $2.91 | $3,515 | -12.20% | ||
| 2024-01-05 | Sale | CHIEF SCIENTIFIC OFFICER | 2,412 0.0065% | $2.91 | $7,019 | -12.20% | ||
| 2024-01-05 | Sale | General Counsel | 2,412 0.0065% | $2.91 | $7,019 | -12.20% | ||
| 2024-01-05 | Sale | Chief Operating Officer | 2,412 0.0065% | $2.91 | $7,019 | -12.20% | ||
| 2023-12-29 | 163,954 0.4272% | $2.38 | $390,211 | +5.00% | ||||
| 2023-12-28 | 409,598 1.0852% | $2.44 | $999,419 | +2.86% | ||||
| 2023-12-27 | 32,134 0.0833% | $2.28 | $73,266 | +9.57% | ||||
| 2023-06-07 | See Below | 15,000 0.0378% | $3.43 | $51,445 | -29.80% | |||
| 2023-06-05 | See Below | 45,000 0.1184% | $3.00 | $135,150 | -16.28% | |||
| 2023-06-02 | See Below | 20,012 0.0493% | $2.82 | $56,422 | -16.56% | |||
| 2023-03-30 | director | 15,000 0.0397% | $2.47 | $37,050 | +10.16% | |||
| 2023-03-29 | director | 10,000 0.0259% | $2.33 | $23,300 | +14.13% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 5402964 13.9723% | $0.58 | 5 | 0 | <0.0001% | |
| Gengos Andrew | CFO and Chief Business Officer | 97532 0.2522% | $0.58 | 3 | 3 | <0.0001% |
| Romano Kelly A | director | 80715 0.2087% | $0.58 | 4 | 0 | <0.0001% |
| EDELMAN JOSEPH | 3695916 9.5578% | $0.58 | 2 | 0 | +8.83% | |
| RTW INVESTMENTS, LP | 10 percent owner | 2668913 6.9019% | $0.58 | 1 | 0 | +9% |
Institutional Investor Ownership
| Perceptive Advisors | $14.8M | 14.1 | 5.4M | 0% | +$0 | 0.01 | |
| Baker Bros Advisors LP | $8.64M | 8.23 | 3.15M | 0% | +$0 | 0.06 | |
| The Vanguard Group | $4.48M | 4.26 | 1.63M | -3.77% | -$175,414.82 | <0.0001 | |
| Simplify Asset Management Inc | $4.09M | 3.9 | 1.49M | 0% | +$0 | 0.39 | |
| Bml Capital Management Llc | $2.47M | 2.35 | 900,000 | -38.12% | -$1.52M | 1.89 |